Management of Disseminated Intravascular Coagulation (DIC)

Introduction to DIC Management

The International Society on Thrombosis and Haemostasis recommends treating the underlying condition and providing hemostatic support as the cornerstone of DIC management, with no evidence supporting the use of hydrocortisone specifically for DIC 1
The management of DIC focuses on treating the underlying disease (such as sepsis, malignancy, trauma, or obstetric complications) and providing supportive care with blood products and, when indicated, anticoagulation, as suggested by the Journal of Thrombosis and Haemostasis 1

In cancer-associated DIC, the primary treatment approach is to treat the underlying malignancy, as recommended by the Journal of Thrombosis and Haemostasis 1
In sepsis-induced DIC, the treatment involves addressing the infection with appropriate antimicrobials, according to the guidelines from the Society of Critical Care Medicine 6

The American College of Chest Physicians suggests transfusing platelets to maintain a count of >50×10⁹/L in patients with active bleeding 2
The administration of fresh frozen plasma (15-30 mL/kg) is recommended for patients with active bleeding, as per the guidelines from the American Association of Blood Banks 2
Cryoprecipitate or fibrinogen concentrate should be administered if fibrinogen levels are <1.5 g/L in patients with bleeding, as recommended by the American College of Chest Physicians 2

The European Society of Intensive Care Medicine recommends heparin as a treatment option primarily for procoagulant forms of DIC with thrombosis 2
Heparin should be avoided in patients with hyperfibrinolytic DIC, as suggested by the International Society on Thrombosis and Haemostasis 2

The Society of Critical Care Medicine recommends against the routine use of corticosteroids in sepsis without shock, as stated in the 2017 guidelines 3
The use of low-dose hydrocortisone in septic shock remains controversial, with the CORTICUS trial showing no mortality benefit and increased secondary infections, as reported in the Annals of Oncology 4
High-dose corticosteroids should not be used due to increased mortality, as recommended by the European Society of Intensive Care Medicine 4

The German Society of Hematology specifically recommends against substitutive doses of hydrocortisone in neutropenic patients with sepsis, as stated in the Annals of Oncology 4
Any decision to use corticosteroids should be based on the underlying condition (such as septic shock or acute respiratory distress syndrome), never for DIC itself, as recommended by the Society of Critical Care Medicine 3, 5